Home
overview

 

SAE Media Group proudly presents the 5th Annual Ophthalmic Drugs Conference taking place on the 21st-22nd of November 2022, in London.

The Ophthalmic drugs industry continues to expand year on year, with an ageing population there is continual demand for advancements in ophthalmic treatments. At the forefront of SAE’s 5th annual event will be a variety of novel drugs which are showing good clinical trial data. Drug delivery will also be an important aspect of the agenda, with advancements in novel technologies. Other key areas will be gene therapy and Artificial Intelligence with developments on the latest drug pipelines and clinical trials.

The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior drug delivery Engineers, Device Testing Managers, Heads of Late-Stage Development, Clinical trial directors and much more.

As SAE’s 5th annual event we look forward to welcoming you back to the conference in November.

Early registration is strongly advised to avoid disappointment.


 

Assess new industry directions through the latest data from ophthalmic clinical trials
Review advanced techniques in treating age-related diseases of ophthalmology
Explore evolving therapeutic potential in undruggable diseases through innovative gene therapies
Examine novel methodologies in delivery technologies being used to further the ophthalmic therapeutic field
Engage in the regulatory landscape of ophthalmic drugs and key considerations for R&D
 

 

- CEOs, CMOs and Researchers from pharmaceutical companies involved in ocular drug development, in addition to biotechnologies involved in ocular drug delivery research.

- Heads and VPs of Retinal Health, Ocular Therapy, Medical Safety, and Ophthalmology.

- Professors, Senior Lecturers, and Specialists in Ocular biology and immunology, and clinical pharmaceuticals.
 

Aerie Pharmaceuticals; Alcon Management SA; Boehringer Ingelheim Biopharmaceuticals Gmbh; Carl Zeiss AG; Centro de Oftamologia Barraquer; Experimentica Ltd; Eyenuk; Global Ophthamology R&D, Santen Inc, USA; Graybug Vision Inc; iVeena; Iveric Bio; Kingston University; Kingston University London; Medicines & Healthcare products Regulatory Agency (MHRA); Medivis; MedPharm Ltd; MHRA; Nanoptima Ltd; Newcastle University; Novartis Pharmaceutical inc; Ophthalmic Drugs 2019; Ophthalmology Times Europe; Optceutics Ltd; ProMed Pharma, LLC; ProQR Therapeutics; RAFARM S.A. Pharmaceuticals; Roche; Roche Products Limited; Santen UK; Spark Therapeutics; Thea Open Innovation; Topivert; twoXAR; UCL Institute of Ophthalmology; UCL School of Pharmacy and UCL Institute of Ophthalmology; University of Oxford; University of Reading; University of Strathclyde;
 

Conference programme

8:00 Registration & Coffee

9:00 Chair's Opening Remarks

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

Naj  Sharif

Naj Sharif, Vice President, Ophthalmology Innovation Center , Santen Inc USA
View Bio

9:10 Combating ocular inflammation

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

• The search for effective non-steroidal anti-inflammatory
agents for non-infectious inflammation
• JAK inhibition as an ocular anti-inflammatory mechanism
• Pre-clinical results of selective JAK inhibitors in animal models of
ocular inflammation

9:50 Exploring recent developments in the potential of port delivery systems

Daniyar Dauletbekov

Daniyar Dauletbekov, Medical Director, Roche Products Ltd
View Bio

• Expanding on benefits of the port delivery system
• Exploring the latest clinical data
• Overcoming the most frequent challenges of the port delivery system
• Delving into the opportunities for more specific drug targeting via
port delivery systems going forward

10:30 Morning Coffee

11:00 How novel delivery devices are improving patient outcomes

Nathan  Wilkinson

Nathan Wilkinson, Ophthalmic Innovation Lead, TTP Plc

• A review of patient, clinician, and therapeutic challenges for
delivering drugs to the eye
• Novel methods of delivery - early signs and opportunities
• Next steps – how delivery devices will shape next
generation therapies and improve patient outcomes

11:40 Topical delivery of selective integrin inhibition

David J Tanzer

David J Tanzer, Chief Medical Officer, Executive Vice President , OcuTerra Therapeutics
View Bio

• A review of the therapeutic potential of integrins in managing retinal
diseases
- What are integrins and what roles do they play in disease?
- An update on the novel integrins being explored as therapeutic
targets in ophthalmology and beyond
• OTT-166 as a novel, selective integrin inhibitor
- An overview of the drug mechanism of action
- Drug distribution to the retina from topical eye drop
- Review of pre-clinical and phase 1 data
- Update on the current phase II clinical trial
- Clinical implications of the drug as a treatment of diabetic
retinopathy
• Future therapeutic potential of selective integrin inhibition

12:20 Use of antisense oligonucleotides for the treatment of inherited retinal diseases

Aniz Girach

Aniz Girach, Chief Medical Officer, ProQR Therapeutics
View Bio

• Antisense oligonucleotides have shown much promise in Ph1/2
Clinical Trials in LCA10 and Usher’s Syndrome
• Lessons learned from Ph 2/3 trial with Sepofarsen for LCA10
• Latest trial data from Interim Analyses for Ultevursen for Usher’s
syndrome and non-syndromic Retinitis Pigmentosa
Aniz Girach, Chief Medical Officer, ProQR Therapeutics

13:00 Networking Lunch

14:00 Suprachoroidal delivery of small molecule suspensions and gene therapy via SCS microinjector

Viral Kansara

Viral Kansara, Vice President of Preclinical Development, Clearside Biomedical
View Bio

• Drug delivery to the suprachoroidal space (SCS) is a clinical reality
after 2021 FDA approval of XIPERETM
• SCS can be reliably accessed via the SCS Microinjector®
• SCS delivery of small molecule suspensions offers targeted,
compartmentalized, and durable drug delivery
• Gene delivery via SCS Microinjector® has potential to be an officebased gene therapy

14:40 Lumevoq gene therapy in Leber Hereditary Optic Neuropathy

Magali Taiel

Magali Taiel, Chief Medical Officer , GenSight Biologics
View Bio

• LHON, a rare disease with high unmet medical need
• Development of Lumevoq gene therapy to treat ND4 LHON patients
• Regulatory pathways
• Key learnings from recent data

15:20 Ocular inflammation associated with gene and cell therapy

Virginia Calder

Virginia Calder, Professor of Ocular Immunology, UCL Institute of Ophthalmology
View Bio

• Immune privilege and the eye
• Inflammation and gene therapy
• Inflammation and cell-based therapy
• What to look for….

16:00 Afternoon Tea

16:30 Strengthening the therapeutic landscape for inherited retinal diseases using genome editing with AAV vectors and CRISPR/Cas9 technologies

Daniel Chung

Daniel Chung, Chief Medical Officer, Sparing Vision

• Expanding on the clinical development of novel gene therapies
including SPVN06
• The benefits of designing gene therapies to act independently of the
causative gene mutation
• An introduction to new clinical trials and future workings

17:10 Panel Discussion: Challenges and opportunities with using genetic therapy for inherited retinal diseases

• Latest trends in genetic therapy for inherited retinal diseases
• Clinical trial endpoints for inherited retinal diseases
• Regulatory guidance/thresholds for clinical trial endpoints
in inherited retinal diseases

Aniz Girach

Aniz Girach, Chief Medical Officer, ProQR Therapeutics
View Bio

Magali Taiel

Magali Taiel, Chief Medical Officer , GenSight Biologics
View Bio

Peter Morgan-Warren

Peter Morgan-Warren, Therapy Area Head Ophthalomolgy, Bayer PLC

Daniel Chung

Daniel Chung, Chief Medical Officer, Sparing Vision

Virginia Calder

Virginia Calder, Professor of Ocular Immunology, UCL Institute of Ophthalmology
View Bio

17:50 Chair’s Closing Remarks and Close of Day One

Naj  Sharif

Naj Sharif, Vice President, Ophthalmology Innovation Center , Santen Inc USA
View Bio

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

Naj  Sharif

Naj Sharif, Vice President, Ophthalmology Innovation Center , Santen Inc USA
View Bio

9:10 Clinical development and regulatory landscape for ophthalmic products

Peter Morgan-Warren

Peter Morgan-Warren, Therapy Area Head Ophthalomolgy, Bayer PLC

• Overview of current regulatory guidance relating to ophthalmic
medicines
• Update on devices and combination approaches for novel ocular
therapeutics
• Special considerations for biologicals, advanced therapies & rare
diseases

9:50 Reviewing the evolving landscape of ophthalmic drugs R&D

10:30 Morning Coffee

11:00 Panel Discussion: The future of AI in retinal disease diagnostics

• The pressures on healthcare systems: why AI assistance is needed
• What AI can enable (touching on community and at-home testing)
• Ones to watch: existing and pipeline solutions to be excited about

Catherine Wyman

Catherine Wyman, Head of Eyecare, TTP Plc

Marion Munk

Marion Munk, Chief Medical Officer, Isarna Therapeutics
View Bio

Pearse Keane

Pearse Keane, Consultant, Moorfields Eye Hospital NHS Foundation Trust
View Bio

Daniela Ferrara

Daniela Ferrara, Principal Medical Director, Genentech / Roche
View Bio

11:40 Transforming the treatment landscape for AMD and DMO with novel technologies

Loic Lhuillier

Loic Lhuillier, COO, Exonate
View Bio

• Exploring modulation of alternative splicing as a new treatment
modality
• Expanding on VEGF as a therapeutic target through VEGF isoforms
• Lessons learned from preclinical discovery and shaping the clinical
development strategy
• Overview of the in-patient Phase I trial

12:20 Dry AMD: Opportunities and Challenges

Daniel Chao

Daniel Chao, Senior Director and Clinical lead, Translational Medicine and Early Clinical Development, Janssen Research and Development
View Bio

• Overview of pathogenesis and natural history of dry AMD
• Delving into the next generation of potential treatments for GA
• Lessons from recent clinical data and considerations for clinical trial
design

13:00 Networking Lunch

14:00 Eybelis: the novel EP2-receptor agonist for glaucoma/ OHT treatment

Naj  Sharif

Naj Sharif, Vice President, Ophthalmology Innovation Center , Santen Inc USA
View Bio

• Role of EP2-receptor agonism in lowering intraocular pressure
• Non-prostaglandin (PG) and PG EP2-receptor agonists
• Differentiating properties of Eybelis as a non-PG EP2 agonist
• Clinical experience and effi cacy of Eybelis in OHT/glaucoma
patients

14:40 Exploring DARC as a biomarker for ocular neurodegenerative disease

Francesca Cordeiro

Francesca Cordeiro, Professor of Retinal Neurodegeneraton and Glaucoma studies, UCL

• Delving in to ANX776 as a fluorescent biomarker of retinal cell stress
• Understanding the use of convolutional neural networks in the
automatic recognition of retinal diseases such as AMD and
glaucoma
• Expanding on key learnings from preclinical data

15:20 Targeting TGF beta 2 mRNA using antisense technology as a new therapeutic option in retinal diseases

Marion Munk

Marion Munk, Chief Medical Officer, Isarna Therapeutics
View Bio

• Our lead compound ISTH0036 is a first in class selective second generation antisense oligonucleotide (ASO) blocking TGF-ß2.
• The phase 1 dose escalation study confirmed the excellent safety
profile
• Currently phase 2 trials are assessing efficacy in wet AMD and DME
• Interim analysis data of the open label phase 2 trial will be presented

16:00 Afternoon Tea

16:30 Reviewing a novel gene therapy approach for chronic ocular diseases

Katie Binley

Katie Binley, Chief Scientific Officer, Ikarovec
View Bio

• Outlining the benefits of a multi-target approach
• Exploring DMO and AMD as gene therapy targets
• Key Learnings from pre-clinical studies

17:10 Exploring novel delivery devices for the treatment of Glaucoma

Omar Sadruddin

Omar Sadruddin, Therapeutic Area Head, Glaucoma, Santen Pharmaceutical
View Bio

  • Reviewing glaucoma as a current therapeutic target within ophthalmology
  • Overcoming the challenges of Aqueous humor drainage in Glaucoma
  • Recent learnings from clinical data on use of Preerflo® Microshunt
  • 17:50 Chairman’s Closing Remarks and Close of Day Two

    Mitchell De Long

    Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    Naj  Sharif

    Naj Sharif, Vice President, Ophthalmology Innovation Center , Santen Inc USA
    View Bio

    +

    FEATURED SPEAKERS

    Aniz Girach

    Aniz Girach

    Chief Medical Officer, ProQR Therapeutics
    Daniel Chao

    Daniel Chao

    Senior Director and Clinical lead, Translational Medicine and Early Clinical Development, Janssen Research and Development
    Daniel Chung

    Daniel Chung

    Chief Medical Officer, Sparing Vision
    Daniela Ferrara

    Daniela Ferrara

    Principal Medical Director, Genentech / Roche
    Daniyar Dauletbekov

    Daniyar Dauletbekov

    Medical Director, Roche Products Ltd
    David J Tanzer

    David J Tanzer

    Chief Medical Officer, Executive Vice President , OcuTerra Therapeutics
    Francesca Cordeiro

    Francesca Cordeiro

    Professor of Retinal Neurodegeneraton and Glaucoma studies, UCL
    Katie Binley

    Katie Binley

    Chief Scientific Officer, Ikarovec
    Loic Lhuillier

    Loic Lhuillier

    COO, Exonate
    Magali Taiel

    Magali Taiel

    Chief Medical Officer , GenSight Biologics
    Marion Munk

    Marion Munk

    Chief Medical Officer, Isarna Therapeutics
    Mitchell De Long

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Naj  Sharif

    Naj Sharif

    Vice President, Ophthalmology Innovation Center , Santen Inc USA
    Nathan  Wilkinson

    Nathan Wilkinson

    Ophthalmic Innovation Lead, TTP Plc
    Omar Sadruddin

    Omar Sadruddin

    Therapeutic Area Head, Glaucoma, Santen Pharmaceutical
    Pearse Keane

    Pearse Keane

    Consultant, Moorfields Eye Hospital NHS Foundation Trust
    Peter Morgan-Warren

    Peter Morgan-Warren

    Therapy Area Head Ophthalomolgy, Bayer PLC
    Viral Kansara

    Viral Kansara

    Vice President of Preclinical Development, Clearside Biomedical
    Virginia Calder

    Virginia Calder

    Professor of Ocular Immunology, UCL Institute of Ophthalmology

    Aniz Girach

    Chief Medical Officer, ProQR Therapeutics
    Aniz Girach

    Aniz Girach, qualified as an Ophthalmologist (specialty in Retina), and worked in Cambridge (UK). After having spent 11 years in the Clinical Practice/Academia, he joined the pharmaceutical industry with Eli Lilly, focusing on retinal diseases. He has in total 24 years industry experience in roles with Merck (astheir Global Head of Ophthalmology) and Alcon, where he was Vice President of Clinical Development; and ThromboGenics, where he was the Global Head of Ophthalmology/Chief Medical Officer overseeing the development and approval of Ocriplasmin (Jetrea)—a first in class biologic therapy for retinal disease. In total, he has led Teams to achieve 4 drug approvals in Ophthalmology. In his role as Chief Medical Officer at Nightstar Therapeutics, he led and oversaw the development of their gene therapy programmes for inherited retinal diseases, prior to their acquisition by Biogen. In addition to being an Honorary  Professor at Wills Eye Hospital, Philadelphia, USA, he is currently the Chief Medical Officer at ProQR Therapeutics, leading the development of RNA therapies for genetic eye diseases. He is a member of 3 Scientific Advisory Boards for international ophthalmic organizations currently, and a reviewer for 5 peer-reviewed journals, including Eye and IOVS. He has been Chief Editor of 4 books and published over 70 abstracts/manuscripts in peer-reviewed journals in Ophthalmology, with numerous invited lectures at national/international ophthalmology meetings. He currently holds Independent Board of Directorship
    positions for 2 Biotech companies. His special interests are Medical Retina, and Genetic Therapy for Rare diseases

    Catherine Wyman

    Head of Eyecare, TTP Plc
    Catherine Wyman

    Daniel Chao

    Senior Director and Clinical lead, Translational Medicine and Early Clinical Development, Janssen Research and Development
    Daniel Chao

    Dr. Chao is Senior Director and Clinical Lead, Translational Medicine and Early Clinical Development at Janssen Research and Development. In his role, he leads early clinical development for retinal diseases, responsible for first in human and phase 2 proof of concept trials of retina assets. Prior to joining Janssen, he was an Assistant Professor of Ophthalmology at the Shiley Eye Institute, University of California San Diego. He is a retina surgeon and led an NIH funded translational research program, authoring over 50 publications and has received numerous awards for his work as a physician scientist.

    Daniel Chung

    Chief Medical Officer, Sparing Vision
    Daniel Chung

    Daniela Ferrara

    Principal Medical Director, Genentech / Roche
    Daniela Ferrara

    Daniela Ferrara MD PhD FASRS is ophthalmologist retina specialist with decades of experience in clinical practice and clinical research. She is currently Principal Medical Director at Genentech/Roche, leading clinical trials in vision threatening retinal diseases and the development of artificial intelligence-based solutions that will enable better patient outcomes. Dr. Ferrara also serves as assistant professor of Ophthalmology at Tufts University School of Medicine, conducting exploratory research for biomarker validation in multimodal retinal imaging, including reading center activities and digital innovation. She is an active member of various ophthalmological and scientific societies in leadership roles, in North and South America.

    Daniyar Dauletbekov

    Medical Director, Roche Products Ltd
    Daniyar Dauletbekov

    Dany Dauletbekov is a well rounded industry clinician-surgeon-scientist, with extensive experience in ophthalmology with the focus on the retina and clinical development spanning early and late phase clinical trials.

    In his current role he is the clinical science lead for the global study on the PDS surgical device implant for treatment of nAMD. He is a clinically trained ophthalmologist, vitreoretinal surgeon with experience of working with gene therapy for inherited retinal diseases, clinical biomarkers for early phase clinical trials, medical devices and most recently medical monitoring for phase 3 clinical trial.
     

    David J Tanzer

    Chief Medical Officer, Executive Vice President , OcuTerra Therapeutics
    David J Tanzer

    David J. Tanzer, MD is board certified, fellowship trained ophthalmologist from the United States and is the Chief Medical Officer and Executive Vice President – Clinical and Medical Affairs with OcuTerra Therapeutics, a clinical stage biotech company headquartered in Boston, Massachusetts.
    With over 25 years of clinical, research, development, launch, and executive leadership experience in the ophthalmology space, serving with the US Navy, Abbott Medical Optics, Johnson & Johnson Vision, and Novartis Pharmaceuticals, Dr. Tanzer is focused on bringing transformational change to therapeutic offerings for patients suffering from retinal vascular diseases by developing OTT166, a safe and effective topical treatment.
     

    Francesca Cordeiro

    Professor of Retinal Neurodegeneraton and Glaucoma studies, UCL
    Francesca Cordeiro

    Katie Binley

    Chief Scientific Officer, Ikarovec
    Katie Binley


    Katie Binley: gained a PhD from the University of Sheffield and joined UK gene therapy company Oxford BioMedica. Katie had a key role in the development and clinical translation over a diverse range of therapeutic areas including several ophthalmic indications before becoming Programme Director for a multi-disciplinary team focused on clinical development of a Parkinson’s gene therapy. In 2019, Katie joined Oxford University spin-out, PepGen as Head of Preclinical Development to advance oligonucleotide therapeutics to treat neuromuscular diseases. In 2020, Katie joined ikarovec as the CSO to focus on the development of novel multi-cistronic gene therapies to treat chronic ophthalmic conditions.
     

    Loic Lhuillier

    COO, Exonate
    Loic Lhuillier

    Loic joined Exonate as Programme Director in 2016 and became Chief Operating Officer in 2019. He has an MSc in Neuroscience from Pierre and Marie Curie University, and a PhD in Cellular and Molecular Biology from the University of Houston. Loic held postdoctoral roles at INSERM (Paris) and Novartis (Basel), before becoming team leader at Lectus Therapeutics (Cambridge). He has spent the last 10 years leading preclinical and clinical projects as a consultant, translational research portfolio manager for the Biomedical Research Centre at King’s College London, and programme manager at Innovate UK.

    Magali Taiel

    Chief Medical Officer , GenSight Biologics
    Magali Taiel

    Dr. Taiel completed her doctorate in Medicine with board certified in Ophthalmology from Lariboisiere Saint Louis
    University, Paris, France, in 1993, and her Associate Professor degree in 1998. Dr Taiel completed her internship at academic Paris hospitals, was an Associate Professor of Ophthalmology, served as an Ophthalmology Department Head, and ran Surgical and Medical Ophthalmology private practice. After 13 years of Ophthalmology public and private practice, Dr Taiel has been engaged in the Pharma Industry for 20 years; she brings extensive experience and expertise in drug clinical development, gene therapy, and medical affairs. She started her carrier at Servier company headquarter, and then worked in Ophthalmology area at Pfizer for several years; she then held international and management positions in various therapeutic areas, including both technical and supervision duties, at Eli Lilly Company for  many years. Then, as VP Clinical Development, she led Clinical Development and Operations, to develop antisense oligonucleotides in Inherited Retinal diseases at ProQR Therapeutics. She then moved to GenSight-Biologics in 2018, to supervise the Medical Department and lead Gene Therapy programs in Inherited Retinal and NeuroOphthalmology diseases, as the CMO of the company. Dr. Taiel has authored numerous protocols and articles published in peer reviewed journals, and made critical contributions to successful clinical development and launch of many products. She brings extensive years of experience from both academic medicine and pharma industry

    Marion Munk

    Chief Medical Officer, Isarna Therapeutics
    Marion Munk

    Prof. Marion R. Munk is a trained MD, PhD, and Uveitis and Medical Retina specialist at the University Clinic Bern in Switzerland and Managing Director at the Bern Photographic Reading Center. She is adjunct Faculty at the Northwestern University, Chicago, USA, Director of Eyegnos Consulting and Chief Medical Officer at Isarna Therapeutics. Marion is author of > 150 scientific articles and book chapters. Her major research interests cover image processing, image analyses, artificial intelligence, macular diseases and posterior uveitis. She is member of the Editorial Board of IOVS, Acta Ophthalmologica, Ocular Inflammation and Infection, Ophthalmologica, BMC Ophthalmology and EyeNet and is providing peer-review for a long list of scientific journals within Ophthalmology.

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Mitchell De Long

    Mitchell A. (Mitch) deLong holds the position of vice president, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 5 INDs and 2 NDAs, with its first FDA approval coming in 2017. Aerie has grown from the initial 3-person team to over 300 employees, and went public on NASDAQ in 2013, where its current valuation is over $2 billion (US). Mitch is lead inventor on over 50 issued US patents, about half of those at Aerie, and has over 100 publications, posters and presentations. Mitch earned his PhD in Synthetic Organic and Medicinal Chemistry at Stanford University, and has two other marketed drugs to his credit.

    Naj Sharif

    Vice President, Ophthalmology Innovation Center , Santen Inc USA
    Naj  Sharif

    Najam (Naj) Sharif, PhD, DSc (Southampton University, UK) has >34-years’ pharmaceutical drug discovery research/development experience covering neuroscience and ophthalmology. His 22-year tenure at Alcon-Novartis resulted in his contributions to the discovery, characterization, development and US FDA approvals of Patanol®/Pataday®/Pazeo® and Emadine® to treat allergic conjunctivitis, and Travatan® and Simbrinza® for the treatment of ocular hypertension / Glaucoma. Currently, he is Vice President, Global Alliances and External Research, Ophthalmology Innovation Center at Santen Inc USA. Dr. Sharif serves many learned Societies (e.g. ISER, elected Trustee of AOPT & Gold Fellow; Gold Fellow of ARVO, and Fellow of British Pharmacological Society (BPS)), Foundations (e.g. The Glaucoma Foundation), and numerous scientific journals. He is the recipient of several honors: the inaugural “Dr. Roger Vogel Award” for ocular pharmaceutical research (ARVO Foundation, 2014), the “Sir James Black Award” for contributions to drug discovery (BPS, 2017), and the “Ernst H. Barany Prize” for outstanding contributions to ocular pharmacology (ISER; 2020). Dr. Sharif is an Adjunct Professor and Graduate Faculty at multiple Universities worldwide where he has advised and supervised MS- and PhD-candidates. Dr. Sharif has published >215 scientific articles, edited 3 books, and holds 24 issued US/EU patents.

    Nathan Wilkinson

    Ophthalmic Innovation Lead, TTP Plc
    Nathan  Wilkinson

    Omar Sadruddin

    Therapeutic Area Head, Glaucoma, Santen Pharmaceutical
    Omar Sadruddin

    Omar Sadruddin, MD, MBA currently serves as Santen’s Therapeutic Area Head for the Glaucoma business. Dr. Sadruddin brings a deep knowledge of ophthalmic devices and pharmaceuticals, with over a decade of experience in leading global clinical strategies and product development from the pre-clinical stage to post-marketing. In his current role, Dr. Sadruddin is responsible for development of medical affairs strategy with a key emphasis on differentiation of products. Prior to joining Santen in 2017, Dr. Sadruddin served as Global Director, Clinical Development-Medical Affairs at Alcon Research Ltd., where he led teams in the planning and conduct of various clinical programs. Previously, he held several positions of progressive responsibility in clinical development and program management, at the Cardiovascular Division of St. Jude Medical in Minnesota. Dr. Sadruddin received his medical degree (MD) from ASU School of Medicine. He has also earned an MBA from Liberty University. Among his many publications are several studies investigating the safety and efficacy of Santen’s MicroShunt glaucoma device.

    Pearse Keane

    Consultant, Moorfields Eye Hospital NHS Foundation Trust
    Pearse Keane

    Pearse Keane is Professor of Artificial Medical Intelligence at UCL Institute of Ophthalmology, and a consultant ophthalmologist at Moorfields Eye Hospital, London. He is originally from Ireland and received his medical degree from University College Dublin (UCD), graduating in 2002.

    In 2016, he initiated a formal collaboration between Moorfields Eye Hospital and Google DeepMind, with the aim of developing artificial intelligence (AI) algorithms for the earlier detection and treatment of retinal disease. In August 2018, the first results of this collaboration were published in the journal, Nature Medicine. In May 2020, he jointly led work, again published in Nature Medicine, to develop an early warning system for age-related macular degeneration (AMD), by far the commonest cause of blindness in many countries.

    In October 2019, he was included on the Evening Standard Progress1000 list of most influential Londoners (https://www.standard.co.uk/news/the1000) and in June 2020, he was profiled in The Economist (https://www.economist.com/technology-quarterly/2020/06/11/the-potential-and-the-pitfalls-of-medical-ai).

    In 2022, he was listed in the “Top 10” of the “The Power List” by The Ophthalmologist magazine, a ranking of the Top 100 most influential people in the world of ophthalmology https://theophthalmologist.com/power-list/2022.

    Peter Morgan-Warren

    Therapy Area Head Ophthalomolgy, Bayer PLC
    Peter Morgan-Warren

    Viral Kansara

    Vice President of Preclinical Development, Clearside Biomedical
    Viral Kansara

    Viral Kansara is Vice President of Preclinical Development at Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing treatments for serious eye diseases. Dr. Kansara is a biopharmaceutical executive with over 15 years of experience and expertise in Ophthalmic drug discovery, development, and delivery. He leverages his vast experience in biopharmaceutical research and development to bring scientific discoveries to clinics. Prior to joining the executive team at Clearside, Dr. Kansara led global cross-functional teams at Novartis Institutes for Biomedical Research, Ophthalmology, and worked at Merck Research Laboratory, Pharmaceutical Sciences. Dr. Kansara has served on several panel discussions; presented at numerous national and international conferences, and authored/co-authored several research articles, review articles, posters, and presentations.

    Virginia Calder

    Professor of Ocular Immunology, UCL Institute of Ophthalmology
    Virginia Calder

    Professor Calder is an immunologist with over 30 years’ experience in inflammatory eye disease research. It is well-known that immunosuppressives can be effective in arresting intraocular immune-mediated diseases but their associated side-effects can be devastating, especially for the eye, when taken long term. The focus of her team is to investigate the underlying immune mechanisms and potential novel therapeutic targets in chronic inflammatory eye diseases such as posterior uveitis, as well as blepharo, atopic and vernal keratoconjunctivitis. This involves utilizing relevant experimental models of disease and validating results with clinically well-defined donor specimens, including conjunctival tissues, aqueous humor, tear fluid, peripheral blood and serum. She has considerable expertise in determining the therapeutic efficacy of novel compounds in experimental disease models, as part of previous and ongoing research collaborations with Pharma.

    Sponsors

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Conference Co-Chair Letter

    Download

    Speaker Biographies

    Download

    Ophthalmic Drugs Brochure 2022

    Download

    Past Attendee List

    Download

    Past Presentation - Jaya Chidambaram - Roche Products Ltd

    Download

    Past Presentation - Gregoire Schwach - Pharma Technical Development Biologics Europe

    Download

    Past Presentation - Raj Thakur - Re-Vana Therapeutics Ltd

    Download

    Past Presentation - Virginia L. Calder - Institute of Ophthalmology

    Download

    Past Presentation - Petra Kozma - Oxurion

    Download

    Sponsors


    Celanese

    Sponsors
    https://vitaldose.com

    Celanese offers the innovative VitalDose® Platform, for targeted ocular delivery of small molecules, biologics, and RNAi to treat conditions such as retinal diseases, glaucoma, and inflammation. VitalDose® EVA provides controlled drug release through implants and inserts. Compared to traditional dose forms, the VitalDose® platform reduces treatment burden, addresses patient adherence issues, and improves bioavailability. We partner with you to enable innovative drug delivery within your desired release profile. Collaborate with experts from our Development & Feasibility Lab to address your drug delivery challenges. We are equipped to design and fabricate functional, loaded prototypes, characterize prototype morphology and release, and provide technical transfer support. With decades of experience in medical and pharmaceutical applications, our customers trust us to provide unrivaled service, world-class expertise, and quality that improves development, enhances manufacturability, and elevates patient care.


    Ora

    Sponsors
    http://www.oraclinical.com

    Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have proudly helped our clients earn more than 55 product approvals and create vision beyond what they see. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and operations management to maximize the value of new product initiatives. Think ophthalmology, think Ora. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn.


    TTP

    Sponsors
    https://www.ttp.com/

    TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies. With a 30+ year history of invention, our multidisciplinary teams are able to deliver across the scope of a project, from research through to ideas, design, engineering and manufacture. TTP’s state-of-the-art technical facilities are part of Europe's largest technology hub in Cambridge, UK. Here, we work across a wide spectrum of industries - including health, telecoms, industrials and consumer - to create breakthrough solutions that bring strong commercial value to clients and the benefits of technology to all.

    Media Partners


    Gene Therapy Net

    Supporters
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Ophthalmology Times Europe

    Supporters
    http://europe.ophthalmologytimes.com/

    Ophthalmology Times Europe, is a physician-driven media brand that presents cutting-edge advancements from around the world in surgery, clinical diagnosis, drug therapy, and technology to elevate the delivery of progressive eye health from physician to patient.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    On Drug Delivery

    Supporters
    http://www.ondrugdelivery.com/subscribe

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out